PAOG Announces Analyst Report Update With $0.015 PPS 12-Month Target For New Cannabis Pharma Business
September 08 2020 - 9:14AM
InvestorsHub NewsWire
Sandusky, OH --
September 8, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc.
(USOTC:
PAOG) today announced Goldman Small Cap Research has published
an analyst research report update. PAOG has recently entered
the cannabis biopharmaceutical sector through two recent
acquisitions. The company acquired a cannabis cultivation
business from Puration, Inc. (PURA).
From Kali-Extracts (KALY),
PAOG acquired a proprietary CBD extract derived from a patented
extraction process and formulated for the treatment of respiratory
disorders.
PAOG’s recently
acquired proprietary formulations are derived from a patented
cannabis extraction process - U.S. Patent No. 9,199,960 entitled,
"METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS PLANT." The formulation tradename is
RespRx. The RespRx CBD Biopharma treatment targets multiple
respiratory-related diseases with a concentration on treating
symptoms of Chronic Obstructive Pulmonary Disease
(COPD).
Goldman Small Cap Research
Excerpt:
“PAO Group
currently trades above its 50-day and 200 day moving averages. This
bullish status, along with its recently updated financials
reporting, should prompt the shares to reach new levels. Moreover,
a review of the financials lends us greater confidence in the
Company’s R&D financing capabilities and the achievement of key
milestones. Thus, we have now introduced a 12-month target of
$0.015, a nearly 5x return from current
levels.”
See the full
Goldman Small Cap Research
Update:
PAOG – Introducing Price Target For Emerging CBD
Pharma
The original Goldman Small Cap Research
Report can be reviewed at:
Under The Radar CBD Pharma Player Could Offer Major
Upside
Learn more at:
www.paogroupinc.com.
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024